LOS ANGELES--(EON: Enhanced Online News)--Goldberg Law PC announces that it is investigating BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) concerning possible violations of federal securities laws.
“a disruption from a large customer that was expected to purchase 2.8 million of succinic acid in Q4 2016, but due to a technical problem in its manufacturing facility postponed the order to 2017.”
If you purchased or otherwise acquired BioAmber shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at firstname.lastname@example.org.
BioAmber revealed that trading announced poor financial results for the 2016 fiscal year, failing to meet its previously issued revenue guidance by $1.3 million. On an earnings conference call, President Fabrice Orecchioni of BioAmber, claimed the poor results were due to “pricing pressures” and “a disruption from a large customer that was expected to purchase 2.8 million of succinic acid in Q4 2016, but due to a technical problem in its manufacturing facility postponed the order to 2017.”
When this information was announced to shareholders, the value of BioAmber stock dropped, causing harm to investors.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at email@example.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.